Equities research analysts at Needham & Company LLC began coverage on shares of Curaleaf (OTCMKTS:CURLF) in a research report issued to clients and investors on Tuesday, The Fly reports. The brokerage set a “buy” rating on the stock.
A number of other analysts have also recently issued reports on CURLF. MKM Partners upgraded Curaleaf from a “sell” rating to a “neutral” rating in a report on Wednesday, November 6th. Cowen initiated coverage on shares of Curaleaf in a research note on Friday, September 13th. They issued an “outperform” rating and a $11.00 target price for the company. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $8.00.
Shares of OTCMKTS:CURLF opened at $6.05 on Tuesday. The business has a 50-day moving average of $5.59 and a two-hundred day moving average of $6.99. Curaleaf has a 12 month low of $3.88 and a 12 month high of $11.73.
Curaleaf Holdings, Inc operates as an integrated medical and wellness cannabis operator in the United States. It cultivates, processes, markets, and/or dispenses a range of cannabis products in various operating markets, including flower, pre-rolls and flower pods, dry-herb vaporizer cartridges, concentrates for vaporizing, concentrates for dabbing, tinctures, lozenges, capsules, and edibles.
Recommended Story: What is the yield curve?
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.